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Objective: Postural instability and gait difficulties (PIGDs) represent debilitating disturbances in Parkinson’s disease
(PD). Past acetylcholinesterase positron emission tomography (PET) imaging studies implicate cholinergic changes as
significant contributors to PIGD features. These studies were limited in quantification of striatal cholinergic synapse
integrity. Vesicular acetylcholine transporter (VAChT) PET ligands are better suited for evaluation of high binding areas.
We examined associations between regional VAChT expression and freezing of gait (FoG) and falls.
Methods: Ninety-four PD subjects underwent clinical assessment and VAChT ([18F]FEOBV) PET.
Results: Thirty-five subjects (37.2%) reported a history of falls, and 15 (16%) had observed FoG. Univariate volume-of-
interest analyses demonstrated significantly reduced thalamic (p = 0.0016) VAChT expression in fallers compared to non-
fallers. VAChT expression was significantly reduced in the striatum (p = 0.0012) and limbic archicortex (p = 0.004) in
freezers compared to nonfreezers. Whole-brain voxel-based analyses of FEOBV PET complemented these findings and
showed more granular changes associated with falling history, including the right visual thalamus (especially the right lat-
eral geniculate nucleus [LGN]), right caudate nucleus, and bilateral prefrontal regions. Freezers had prominent VAChT
expression reductions in the bilateral striatum, temporal, and mesiofrontal limbic regions.
Interpretation: Our findings confirm and extend on previous PET findings of thalamic cholinergic deficits associated with
falling history and now emphasize right visual thalamus complex changes, including the right LGN. FoG status is associ-
ated with reduced VAChT expression in striatal cholinergic interneurons and the limbic archicortex. These observations
suggest different cholinergic systems changes underlying falls and FoG in PD.
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Advancing Parkinson’s disease (PD) is associated withdebilitating postural instability and gait difficulties
(PIGDs), such as falls and freezing of gait (FoG).1 The
Sydney Multicenter Study of PD found that dopamine
nonresponsive PIGDs dominate motor function 15 years
after initial assessments and includes frequent falls, occurring
in 81% of subjects.2 Another incident cohort reported that
68% of PD subjects exhibited postural instability at 10-year
follow-up.3 Dopaminergic medication “on” freezing has
been reported in 38% of a large series of subjects with PD.4
Absent dopaminergic therapy responses implicates
nondopaminergic mechanisms in worsening PIGD motor
features. Major populations of central nervous system cholin-
ergic neurons include the basal forebrain (BF) complex, the
brainstem pedunculopontine nucleus/lateral dorsal tegmental
complex (PPN/LTDC), and striatal cholinergic interneurons.
We previously associated PPN/LTDC-thalamic and BF
corticopetal cholinergic projection system degeneration with
falls and slow gait speed in PD, respectively.5,6 Using dopa-
minergic, acetylcholinesterase (AChE) and β-amyloid posi-
tron emission tomography (PET) imaging, we also reported
reduced striatal dopaminergic terminals, reduced diffuse cor-
tical cholinergic terminals, and more severe cortical amyloi-
dopathy in PD freezers compared to nonfreezers.7
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Our previous AChE PET imaging studies were limited
because of the ligand’s inability to reliably estimate tracer
hydrolysis rates in high binding areas, such as the striatum
or cerebellum.8 This limits identification of potentially rele-
vant fall- or FoG-associated markers.9 [18F]-FEOBV is a
PET radioligand that selectively binds to the vesicular ace-
tylcholine transporter (VAChT).10 An advantage of
[18F]-FEOBV PET is that ligand binding in regions with
high cholinergic terminal density can be more accurately
estimated.11
The objective of this study is a detailed in vivo exami-
nation of regional cerebral, including cortical and subcorti-
cal, VAChT expression in PD subjects with PIGD motor
features. We hypothesized that distinct distributed patterns
of subcortical and cortical cholinergic projection system
changes are associated with FoG and falls in PD. Based on
our previous AChE studies, we hypothesized a central role
for thalamic involvement for falls and cortical changes
underlying FoG.
Patients and Methods
Subjects and Clinical Test Battery
This study involved 94 subjects with PD (72 males;
22 females), mean age 67.9  7.6 (standard deviation [SD];
range, 51–93) years. PD subjects met the UK Parkinson’s
Disease Society Brain Bank clinical diagnostic criteria.12 Sub-
jects with evidence of large vessel stroke or other intracranial
lesions on anatomic imaging were excluded. The Interna-
tional Parkinson and Movement Disorder Society revised
UPDRS (MDS-UPDRS) motor examination was performed
in the morning in the dopaminergic medication ‘off ’ state.
Subjects completed the Montreal Cognitive Assess-
ment (MOCA) with mean score of 26.2  3.3 (range,
10–30).13 Mean duration of disease was 6.0  4.5 (range,
1–30) years. The mean motor examination score on the
MDS-UPDRS was 33.9  13.8 (range, 2–74).14
Thirty-one PD subjects were taking a combination of
dopamine agonist and carbidopa-levodopa medications,
47 were using carbidopa-levodopa alone, 10 were taking
dopamine agonists alone, and 6 were not receiving dopami-
nergic drugs. Mean levodopa equivalent dose (LED) was
655.5  397.8 mg (range, 0.0–1,902.5).15 No subjects
were treated with anticholinergic or cholinesterase inhibitor
drugs. Most subjects had moderate severity of disease: 6 sub-
jects in stage 1, 3 in stage 1.5, 20 in stage 2, 40 in stage 2.5,
20 in stage 3, and 5 in stage 4 of the modified Hoehn and
Yahr classification with mean stage of 2.45  0.60.
Fall and FoG Assessment
Participants were asked about a history of falling. A fall was
defined as an unexpected event during which a person falls
to the ground. The presence or absence of FoG was based on
clinical examination and directly observed by the clinician
examiner based on a nonzero score on item 3.11 “Freezing of
Gait” of the MDS-UPDRS motor examination.14 For most
reliable assessment, FoG classification should be based upon
objective confirmation by an experienced observer during
clinical assessment rather than on patient recollection.16 This
study was approved by the Institutional Review Boards of
the University of Michigan School of Medicine and Veterans
Affairs Ann Arbor Healthcare System. Written informed
consent was obtained from all subjects.
Imaging Techniques
Magnetic resonance imaging (MRI) was performed on
a 3 Tesla Philips Achieva system (Philips, Best, The
Netherlands). A three-dimensional (3D) inversion recovery-
prepared turbo field echo was performed in the sagittal plane
using repetition time/echo time/inversion time = 9.8/4.6/
1041 ms; turbo factor = 200; single average; field of view
(FOV) = 240 × 200 × 160 mm; acquired matrix = 240
× 200 × 160 slices; and reconstructed to 1-mm isotropic
resolution.
PET imaging was performed in 3D imaging mode
with a Siemens ECAT Exact HR+ tomograph or Biograph
6 TruPoint PET/computed tomography scanner (Siemens
Molecular Imaging, Inc., Knoxville, TN), which acquire
63 transaxial slices (slice thickness: 2.4 mm) over a 15.2-cm
axial FOV. Images were corrected for scatter and motion.
Subjects were scanned in the dopaminergic medication “on”
state.
[18F]FEOBV was prepared as described previ-
ously.17,18 [18F]-FEOBV delayed dynamic imaging was per-
formed over 30 minutes (in six 5-minute frames) starting
3 hours after an intravenous bolus dose injection of 8 mCi
[18F]-FEOBV.11 PET imaging frames were spatially coregis-
tered within subjects with a rigid-body transformation to
reduce the effects of subject motion during the imaging
session.19 Statistical parametric mapping (SPM) software
(SPM12; Wellcome Trust Centre for Neuroimaging, Uni-
versity College, London, England [https://www.fil.ion.ucl.
ac.uk/spm/software/spm12/]) was used for PET-MRI regis-
tration using the cropped T1-weighted MR volumetric scan.
Freesurfer software (http://surfer.nmr.mgh.harvard.edu) was
used to define cortical and subcortical MR gray volumes of
interest (VOIs).
A white matter reference tissue approach was used to
determine VAChT binding as previously reported.20,21 This
approach departs from previously used cerebellar gray matter
reference regions.11 This is appropriate as cholinergic termi-
nal changes may occur in cerebellar cortices in parkinsonian
disorders,22 which may potentially bias findings using this
reference region in these particular patient populations. Dis-
tribution volume ratios (DVRs) were calculated from ratio
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of summed six delayed imaging frames (3 hours after injec-
tion) for gray matter target and white matter reference
tissues.21
VOI and Voxel-Based Brain PET Analysis
VOI and voxel-based methods provide complementary
information. The following bilaterally averaged VOIs were
defined for the striatum (putamen and caudate nucleus),
thalamus, cerebellar gray matter, brainstem, limbic archi-
cortex (hippocampus and amygdala), and neocortex based
on combination of individual labels from the Mindboggle-
101 data set segmented in FreeSurfer.
Complementary whole-brain voxel-based [18F]FEOBV
PET analyses were performed to explore more granular
regional brain VAChT binding changes that may not be
captured or missed by predefined VOIs. Voxel-based statis-
tical analysis was performed using SPM12 software on the
parametric [18F]FEOBV DVR images of all subjects. For
SPM analysis, all brain images were spatially normalized to
Montreal Neurological Institute template space using DAR-
TEL normalization protocol and smoothed with a Gaussian
kernel of 4-mm full width half maximum to adjust the
anatomical variability between the individual brains and
to enhance the signal-to-noise ratio.
Statistical Analysis
Standard pooled-variance t test or approximate t tests based
on rank normalization were used for statistical group compar-
isons (SAS version 9.3; SAS institute Inc., Cary, NC). Step-
wise logistic regression was performed using fall or FoG
status as the outcome parameter and VOI-based regional
VAChT binding as PET regressors. Analyses were performed
using SAS software (version 9.3; SAS institute). Statistical
inferences were made on meeting two-tailed testing require-
ment for α < 0.05 and Holm-Bonferroni correction for mul-
tiple testing for all clinical group comparisons and brain PET
VOI analyses.
To complement the VOI-based analyses, we per-
formed two main exploratory whole-brain voxel-wise ana-
lyses to compare the total group of fallers versus nonfallers
and total group of freezers versus nonfreezers, respectively.
For this purpose, we designed a two-sample voxel-based
t test to compare different groups. We thresholded statisti-
cal parametric maps at p = 0.0125 with a minimum cluster
size of 50 voxels. We then identified clusters of significant
voxels in anatomic subregions that were consistent with our
hypotheses and/or concordant with regional cerebral results
demonstrated by these VOI analyses. Statistically significant
clusters, corrected for multiple comparisons using family-
wise error (FWE), were identified using the small volume
(radius of VOI at 5 mm) voxel-based method as previously
reported.23
Finally, we performed post-hoc exploratory analyses
to further evaluate any regional brain findings of these main
voxel-based analyses by comparing subsets of patients of
various combinations of fall and FoG status for more pure
mechanistic analyses underlying fall and FoG status, respec-
tively. Because some of the regional brain locomotor or
motor control region may represent anatomically small
structures (ie, clusters smaller than 50 voxels) we did not fil-
ter out the parametric images for a minimal cluster size. Sig-
nificant clusters were also identified by the small volume
FWE correction method.23
Results
Clinical Findings: Falls and Freezing Status
Thirty-five subjects (37.2%) reported a history of falls.
Fallers had longer duration of disease, greater motor disease
severity, higher Hoehn & Yahr scores, higher LED, higher
frequency of reporting acting out of dreams, and worse cog-
nitive performance than nonfallers; however, there were no
significant differences in sex distribution or age (Table 1).
FoG was present in 15 subjects (16.0%). Freezers were
older, had longer duration of disease, higher mean Hoehn
and Yahr score, more severe motor disease, higher LED, and
worse cognitive performance than nonfreezers (Table 2).
There were no significant differences in sex distribution or
frequency of reporting acting out of dreams between groups.
Regional Cerebral FEOBV VOI PET Findings in
Fallers
Univariate VOI analyses (corrected for multiple testing) dem-
onstrated significantly reduced thalamic (p = 0.0016) VAChT
expression in fallers compared to nonfallers (Table 3).
None of the other regions retained significance after correc-
tion for multiple testing. In a post-hoc analysis, we explored
whether this finding was lateralized and entered the left and
right thalamic VOIs in a backward step-wise logistic regres-
sion analysis yielding right thalamic VAChT binding as the
single regressor meeting the model’s entry criteria (Wald
χ2 = 9.1; p = 0.0025).
Regional Cerebral FEOBV VOI PET Findings in
Freezers
Univariate VOI analysis showed reduced striatal and limbic
archicortical VAChT binding in freezers compared to non-
freezers (Table 4). These two regions were entered in back-
ward step-wise logistic regression analysis yielding striatal
VAChT binding as the single regressor meeting the model’s
entry criteria (Wald χ2 = 8.6; p = 0.0034). In a post-hoc
analysis, we explored whether this involved the lateralized
caudate nucleus versus the lateralized putamen. The left and
right putamina and caudate nuclei VAChT VOIs were
entered in backward step-wise logistic regression analysis
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yielding the right caudate nucleus VAChT binding as the
single regressor meeting the model’s entry criteria (Wald
χ2 = 9.3; p = 0.0023).
Post-Hoc Confounder Variable Analysis
A post-hoc analysis of covariance (ANCOVA) was per-
formed to determine possible confounder effects of signifi-
cant clinical variables (LED, MOCA score, and duration of
disease) where LED and duration of disease are proxy vari-
ables for overall disease severity. The total model for fall sta-
tus was significant (F(4,89) = 3.53; p = 0.01) with significant
effects for thalamic VACHT binding (F = 6.17; p = 0.015),
borderline for MOCA scores (F = 3.30; p = 0.072), but
not significant for duration of disease or LED. Similar
ANCOVA for FoG status demonstrated a significant overall
model (F(4,89) = 3.26; p = 0.015) with significant effect for
striatal VAChT binding (F = 8.14; p = 0.0054), but no sig-
nificant covariate effects for duration of disease, MOCA,
or LED.
Voxel-Based Whole-Brain FEOBV PET Analyses
Whole-brain voxel-based analyses were performed to com-
pared the total of 35 fallers to 59 nonfallers (analysis 1) and
a total of 15 subjects with FoG compared to 79 nonfreezers
(analysis 2).
Main Whole-Brain Voxel-Based Analysis 1: PD
Fallers Versus Nonfallers (All Fallers)
Significant FEOBV binding reductions (FWE-corrected
p values ranging from 0.032 to 0.040) were found in the
TABLE 2. Mean (SD) Values of Demographic, Clinical, and Cognitive Data
PD without FoG (n = 79) PD With FoG (n = 15) Statistical Significance
Age, yr 66.9  6.8 73.1  9.4 t = 3.1; p = 0.003
Sex (females/males) 20/59 2/13 χ2 = 1.0; p = 0.32
Duration of motor disease (yr) 5.4  4.5 9.1  3.7 t = 3.8; p = 0.0003
Hoehn and Yahr stage 2.3  0.5 3.2  0.6 t = 6.1; p < 0.0001
Motor MDS-UPDRS 31.2  12.6 48.5  10.7 t = 5.0; p < 0.0001
Montreal Cognitive Assessment 26.8  2.7 23.5  4.7 t = 3.2; p = 0.0019
Acting out dreams (yes/no) 43/36 7/7 (n = 14) χ2 = 0.4; p = 0.004
LED (mg/day) 579.1  366.3 1,057.9  312.0 t = 4.7; p < 0.0001
Sex distribution is presented as proportions. Levels of statistical differences between groups are also presented.
FoG = freezing of gait; LED = levodopa equivalent dose; PD = Parkinson’s disease; SD = standard deviation.
TABLE 1. Mean (SD) Values of Demographic, Clinical, Cognitive Data in the Patients With PD Without Versus
With Falls (Total n = 94)
PD Nonfallers (n = 59) PD Fallers (n = 35) Statistical Significance
Age, yr 67.2  7.3 68.9  8.2 t = 1.1; p = 0.29
Sex (females/males) 16/43 6/29 χ2 = 1.2; p = 0.26
Duration of motor disease (yr) 4.9  3.5 8.0  5.4 t = 3.5; p = 0.0008
Hoehn and Yahr stage 2.2  0.6 2.8  0.6 t = 4.7; p < 0.0001
Motor MDS-UPDRS 29.9  10.5 40.7  15.5 t = 4.0; p = 0.0001
Montreal Cognitive Assessment 27.0  2.3 25.0  4.2 t = 2.4; p = 0.02
History of acting out dreams (yes/no) 25/34 25/9 (n = 34) χ2 = 0.4; p = 0.004
LED (mg/day) 571.2  333.9 797.6  457.7 t = 2.5; p = 0.014
Sex distribution is presented as proportions. Levels of statistical difference between groups are also presented.
LED = levodopa equivalent dose; PD = Parkinson’s disease; SD = standard deviation.
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total group of PD fallers (n = 35) versus nonfallers (n = 59)
in the dorsomedial thalamus (right greater than left), right
lateral geniculate nucleus (LGN), right pulvinar, right head
of the caudate nucleus, prefrontal, right temporopolar, right
mesiotemporal, right more than left insula, superior vermis,
and bilateral superior cerebellar peduncle regions (Fig 1).
Additional FEOBV binding reductions were present in the
anterior cingulate cortex. There were no areas of signifi-
cantly increased FEOBV binding in fallers compared to
nonfallers.
Main Whole-Brain Voxel-Based Analysis 2: PD
Freezers Versus Nonfreezers (All Freezers)
Whole-brain voxel-based analysis comparing freezers (n = 15)
to nonfreezers (n = 79) demonstrated significant FEOBV
binding reductions (FWE-corrected p values ranging from
0.034 to 0.041) in the left hippocampal region and bilateral
prefrontal and bilateral anterior cinguli (Fig 2). Additional
reductions were observed in the striatum, including right
more than left caudate and accumbens nuclei and putamina,
bilateral limbic archicortex, bilateral gyri recti, right LGN,
and right midcingulate cortex regions (Fig 2).
Post-Hoc Exploratory Voxel-Based Analysis of
Specific Subsets of Variable Combinations of Fall
and FoG Status
Finally, we compared subsets of subjects with variable
combination of falls and/or FoG status to allow a more
“pure” mechanistic assessment of intrinsic fall and FoG
phenomena. The first post-hoc analysis compared PD
fallers without FoG (n = 24) versus PD nonfallers without
FoG (n = 55) for more pure assessment of fall patterns.
The second post-hoc analysis compared fallers with FoG
(n = 11) to fallers without FoG (n = 24) to better capture
the intrinsic pattern changes associated with pure freezing
motor behaviors.
TABLE 3. Mean (SD) Values of Bilaterally Averaged [11C]FEOBV VAChT Distribution Volume Ratios in the
Patients With PD Without Versus With Falls
PD Nonfallers (n = 59) PD Fallers (n = 35) Statistical Significance
Brainstem 1.31  0.09 1.26  0.13 t = 2.1; p = 0.042
Cerebellum 1.34  0.22 1.26  0.19 t = 1.5; p = 0.15
Thalamus 1.91  0.18 1.80  0.24 t = 3.3; p = 0.0016*
Striatum 4.50  0.54 4.33  0.69 t = 1.5; p = 0.14
Limbic archicortex 1.89  0.15 1.84  0.18 t = 1.5; p = 0.15
Neocortex 1.05  0.08 1.04  0.08 t = 0.9; p = 0.38
Levels of statistical differences between groups are also presented (values with an asterisk remain significant after correction for Holm-Bonferroni multiple testing).
FEOBV = fluoroethoxybenzovesamicol; PD = Parkinson’s disease; SD = standard deviation; VAChT = vesicular acetylcholine transporter.
TABLE 4. Mean (SD) Values of Bilaterally Averaged [11C]FEOBV VAChT Distribution Volume Ratios in the
Patients With PD Without Versus With FoG
PD Without FoG (n = 79) PD With FoG (n = 15) Statistical Significance
Brainstem 1.30  0.10 1.24  0.15 t = 1.6; p = 0.12
Cerebellum 1.32  0.22 1.25  0.18 t = 1.0; p = 0.33
Thalamus 1.89  0.20 1.76  0.21 t = 2.1; p = 0.04
Striatum 4.53  0.56 3.98  0.64 t = 3.3; p = 0.0012*
Limbic archicortex 1.90  0.15 1.76  0.17 t = 3.0; P = 0.004*
Neocortex 1.05  0.08 1.04  0.09 t = 0.5; p = 0.6
Levels of statistical differences between groups are also presented (values with an asterisk remain significant after correction for Holm-Bonferroni multiple
testing).
FEOBV = fluoroethoxybenzovesamicol; FoG = freezing of gait; PD = Parkinson’s disease; SD = standard deviation; VAChT = vesicular acetylcholine
transporter.
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Post-Hoc Exploratory Voxel-Based Analysis 1:
PD Fallers Without FoG Versus PD Nonfallers
Without FoG (Pure Falls)
We compared the number of PD fallers without FoG to PD
nonfallers also without FoG to explore a more neurobiologi-
cal pattern of intrinsic fall mechanisms. Significant (FWE-
corrected p values ranging from 0.033 to 0.046) clusters
included the right LGN, right caudate nucleus, right premo-
tor cortex, right lateral temporal, right frontal eye field, right
temporopolar cortex, right posterior cingulum, right proxi-
mal lingual gyrus, and bilateral prefrontal regions (Fig 3).
Additional reductions were observed in the right more than
left sensorimotor cortices.
Post-Hoc Exploratory Voxel-Based Analysis 2:
PD Fallers With FoG Versus PD Fallers Without
FoG (Pure FoG)
We also compared fallers with FoG to fallers without FoG
to better capture the intrinsic changes underlying freezing
motor behaviors and found significant clusters of reduced
VAChT binding (FWE-corrected p levels ranging from
0.034 to 0.046) in the left hippocampus, right temporal
lobe, anterior cingulum, and cerebellum (Fig 4). Additional
reductions were observed in the bilateral basal ganglia, lim-
bic archicortex, right LGN, and right insula.
Finally, a post-hoc confounder analysis to determine
any possible effect of LED medication effects on the regional
cholinergic binding did not significantly change the main
findings.
Discussion
Although falls and FoG are interconnected episodic
phenomena,1 our findings show that these represent par-
tially distinct entities with probable differing pathophysiol-
ogy. VOI-based analysis identified the thalamus and
striatum as critical regions contributing to falls and FoG in
PD, respectively. Thalamic cholinergic deficits, for example,
are associated with impaired postural reflexes, whose under-
lying pathophysiology may differ from that leading to
FoG.24,25 We found that history of falls is associated with
cholinergic projection system changes in which the thala-
mus is likely a key node whereas FoG is associated with
changes for which the caudate nucleus is likely a key node.
FIGURE 1: Main voxel-based SPM analysis comparing the total group of PD fallers versus nonfallers. Significant FEOBV binding
reductions were found in the total group of PD fallers versus nonfallers in the dorsomedial thalamus (right greater than left), right
LGN, right pulvinar, right head of the caudate nucleus, prefrontal, right temporopolar, right more than left insula, superior vermis,
and bilateral superior cerebellar peduncle regions. Additional FEOBV binding reductions were present in the anterior cingulate
cortex. FEOBV = fluoroethoxybenzovesamicol; LGN = lateral geniculate nucleus; PD = Parkinson’s disease.
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[18F]FEOBV is a specific VAChT ligand and marker
of cholinergic terminals.10 The regional distribution of
[18F]FEOBV binding in human brain is identical to the dis-
tribution of cholinergic terminals described in postmortem
human brain studies.26 The diminished [18F]FEOBV bind-
ing we describe in brain regions of PD falling and/or freez-
ing subjects compared to those without these PIGD features
is most compatible with degeneration (or greater degenera-
tion) of cholinergic terminals. This inference is consistent
with preclinical studies demonstrating that lesions of the BF
complex or PPN result in significantly diminished
[18F]FEOBV binding in target regions of these projec-
tions.27,28 Similarly, Schmitz et al demonstrated a good cor-
relation between cortical [18F]FEOBV binding deficits and
basal forebrain nuclei atrophy in subjects with probable early
Alzheimer’s disease.29 Another important point for inter-
preting our results is that whereas basal forebrain projections
to neocortex were conceived historically as a diffuse projec-
tion system, recent data indicate that subpopulations of BF
cholinergic neurons project to relatively restricted cortical
regions.30 The VOI and VB cortical [18F]FEOBV binding
reductions we describe likely reflect degeneration or dys-
function of subpopulations of BF cholinergic neurons.
Diminished [18F]FEOBV binding in the amygdala and hip-
pocampal formation of PD subjects with FoG likely reflects
disproportionate degeneration of more rostral BF cholinergic
projection neurons. Similarly, diminished frontal cortical
[18F]FEOBV binding in PD subjects with history of falls
likely reflects preferential loss of subpopulations of more
caudal BF cholinergic projection neurons.
Falling is a serious axial motor impairment in PD.
There is converging evidence that cholinergic input from
the PPN/LDTC to the thalamus may play an important role
in the pathophysiology of falls in PD.5,7,24,25 Our present
study, using a more specific PET cholinergic terminal ligand
and a different population of subjects, confirms our previous
AChE PET imaging findings that PD fallers have lower den-
sity of thalamic cholinergic nerve terminals compared to
nonfallers.5 This inference is consistent with a postmortem
study that found evidence of lower PPN cholinergic neuron
counts in PD subjects with falls during life compared to
nonfallers.24 Although the human thalamus also receives
FIGURE 2: Main voxel-based SPM analysis comparing the PD freezers to the nonfreezers demonstrated significant VAChT binding
reductions in the left hippocampal region and bilateral prefrontal and bilateral anterior cinguli. Additional reductions were seen in the
striatum, including right more than left caudate and accumbens nuclei and putamina, bilateral limbic archicortex, bilateral gyri recti, right
LGN, and right mid-cingulate cortex regions. LGN = lateral geniculate nucleus; PD = Parkinson’s disease; VAChT = vesicular
acetylcholine transporter.
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cholinergic inputs from the BF complex, these are sparser
than PPN/LDTC afferents and it is likely that the con-
siderable majority of thalamic terminals arise in the
PPN/LDTC complex.31 This is particularly true for visual
thalamic nuclei such as the pulvinar and LGN, which con-
tain only sparse BF terminals.31 Although cholinergic
thalamic afferents likely play a critical role in the patho-
physiology of falls in PD, PPN/LTDC-thalamic cholinergic
degeneration typically occurs in the setting of BF losses,32
suggesting that extensive brain cholinergic projection system
deficits are also implicated in falls in PD.
Our post-hoc VOI analysis identified the right thala-
mus as the most significant hypocholinergic brain region
associated with falls. A significant limitation of the VOI-
based approach, however, is that anatomic resolution is lim-
ited to predefined VOIs and/or Freesurfer parcellation. This
particularly limits the analysis of the thalamus, where no val-
idated nuclear parcellation is available at the present time.
Complex phenomena like falls and FoG likely reflect
circuit-level alterations whereas the VOI-based analyses
identify critical nodes; it may underestimate the extent of
circuit level changes. To explore circuit level alterations, we
supplemented the VOI analysis with a voxel-based analysis.
The voxel-based analysis suggests a more specific role of the
right visual thalamus, including the pulvinar and LGN, in
the pathophysiology of falls in PD. Most models of vision
treat the LGN as a passive relay station to the primary visual
cortex. Accumulating data, however, indicate that the pulvi-
nar and LGN are important nodes in corticothalamocortical
circuits modulating attentional function and the coordina-
tion of cortical regions for attending to stimuli and tasks.33
We can only speculate as to why we find asymmetric
abnormalities in the visual thalamus (fallers) and caudate
(freezers). The ventral attention network, which responds
to unexpected stimuli and is highly integrated with the
visual system, lateralizes to the nondominant hemisphere.34
Hypothetically, lateralization of unique brain function(s)
may require higher ipsilateral neural network or neuronal
metabolic demands, which may, in turn, increase vulnera-
bility to early degeneration.
These observations suggest that impaired processing
of visual information relevant for safe ambulation may be
FIGURE 3: Post-hoc exploratory voxel-based SPM analysis comparing the subset of PD fallers without FoG to PD nonfallers also
without FoG. There were more isolated reductions in the right LGN, right caudate nucleus, right premotor cortex, right frontal eye
field, right temporopolar cortex, right lateral temporal, right posterior cingulum, right proximal lingual gyrus, and bilateral prefrontal
regions. Additional reductions were seen in the right more than left sensorimotor cortices. FoG = freezing of gait; LGN = lateral
geniculate nucleus; PD = Parkinson’s disease.
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compromised in PD fallers. It is conceivable that vulnera-
bility of the right visual thalamus complex may be related
to previous observations of a subtle left hemineglect in PD
consisting of a directional (right hemifield) bias of initial
visual exploration.35 Relative deficiency of detecting salient
environmental visual cues from the left hemifield may be
a potential mechanism to explain increased fall risk with
right LGN dysfunction. There is also evidence of percep-
tual asymmetry in perceptuomotor tasks without visual
input. An upper body truncal rotation experiment showed
evidence of contraction of left external hemispace relative
to the right hemispace, possibly affecting generation and
execution of motor commands through disease progression
in PD.36
The voxel-based analysis implicates other brain regions
as important contributors to the etiology of falls, notably the
frontal cortex. Reduced cortical cholinergic signaling likely
results in decreased transfer of cortical sensory and move-
ment cues to subcortical structures, such as the striatum,
degrading sensorimotor integration.37 Similarly, altered neo-
cortical regulation of movement may underlie some forms
of FoG.38 FoG is a debilitating feature of PD that becomes
more frequent with advancing disease. The magnitude of
nigrostriatal dopaminergic denervation is an important path-
ophysiological element of FoG.39 Our study confirms that
the presence of FoG is related to longer duration of disease,
more severe parkinsonian motor ratings, and higher LED
levels. Striatal dopamine deficits, however, are likely not the
only factor in FoG. First, our confounder covariate analysis
did not show a significant covariate effect for LED. Second,
the presence of FoG and its degree of responsiveness to
dopaminergic medications correlates with exposure to anti-
cholinergic drugs.4 Freezing in PD may result from striatal
dopamine loss and cortical cholinergic deafferentation, yield-
ing striatal circuitry that lacks information about the efficacy
of gait, posture, and movement and that is impaired in
selecting and sequencing motor actions, resulting in slow
and reluctant movements or fails to initiate movement
altogether.37
Past imaging studies found evidence of disruption of
cortical function in FoG, including regions or networks
involved in executive functions and sensorimotor perception
in PD.38,40–42 For example, a resting-state fMRI brain
connectivity study identified reduced connectivity in right
FIGURE 4: Post-hoc exploratory voxel-based SPM analysis comparing fallers with FoG to fallers without FoG showing more specific
cholinergic transporter reductions in the left hippocampus, right temporal lobe, anterior cingulum, and cerebellum. Additional
reductions were seen in the bilateral basal ganglia, limbic archicortex, right LGN, and right insula. FoG = freezing of gait; LGN = lateral
geniculate nucleus.
546 Volume 85, No. 4
ANNALS of Neurology
cortical frontoparietal “executive-attention” and right occipi-
totemporal “visual” networks in PD with FOG suggesting a
role of network connectivity disruption.41 A diffusion tensor
MRI study showed evidence of reduced connectivity
between connectivity of the PPN with the cerebellum, thala-
mus, and multiple regions of the frontal cortex.43 Moreover,
these structural differences were observed solely in the right
hemisphere of patients with FoG.
Our voxel-based analysis suggests specific roles of stria-
tal cholinergic interneurons, especially of the right caudate
nucleus, and limbic archicortical structures in FoG. Unlike
the predominant motor connections of the putamen, the
caudate nucleus is a node in more cognitive and affective cir-
cuits.44 FoG is notably exacerbated by anxiety and often
arises in situations where there are competing cognitive
demands. These observations suggest that nonmotor (cogni-
tive, affective, and emotional) functions of the caudate
nucleus are relevant for FoG. Degeneration or dysfunction
of caudate cholinergic interneurons may disrupt corticostria-
tal information flow underlying the integration of goal
directed behavior and sensorimotor integration and is a
plausible substrate for altered network behavior underlying
FoG.45
Dysfunctional limbic circuitry may underlie freezing
of gait in PD. A recent resting-state brain MRI found abnor-
mal connectivity between the right amygdala and striatum
in freezers compared to nonfreezers.46 Hippocampal abnor-
malities may point to altered spatial sensorimotor integra-
tion functions. FoG is notoriously associated with anxiety,
and the amygdalar cholinergic abnormalities we detected
suggest a concrete substrate for anxiety as a determinant of
FoG in PD.47
REM sleep without atonia may be a comorbid feature
of patients with PD exhibiting FoG.48 We previously
reported reduced limbic, cortical, and brainstem-thalamic
acetylcholinesterase hydrolysis rates in PD patients with
REM sleep behavior, suggesting partially shared cholinergic
pathophysiology of these two phenomena.49 We did not
find a significant difference in the frequency of dream
enactment behaviors in the freezers versus nonfreezers. Our
sample size, however, was small. We found an unexpected
significant difference in reporting of dream enactment
behavior in the fallers compared to the nonfallers. Given
that isolated falls typically precede freezing motor behaviors
during the natural course of the disease in PD,50 it is possi-
ble that brainstem-thalamic cholinergic changes may be a
greater determinant of this parasomnia than more anterior
striatal or limbic changes. Further research is needed to
explore this hypothesis.
A limitation of our study is that assessment of FoG
was not based on special maneuver to identify specific sub-
types of freezing motor behaviors, like making turns or
passing through narrow doorways. The absence of a spe-
cific provocative FoG assessment protocol may also
explain the relatively low frequency of freezing behaviors
in our study sample. Consequently, this may result in a
relative underestimation of effect size estimates of our
study. However, our assessment protocol of direct obser-
vation of freezing behavior will result in a very high speci-
ficity of FoG classification.
In this study, we found that differential degeneration
of cholinergic projections play distinct roles in postural and
gait disturbances of PD. Our VOI analysis findings inde-
pendently confirm previous observations that impaired
integrity of thalamic cholinergic nerve terminals contrib-
utes to the pathophysiology of falls in PD. Our voxel-
based analysis suggests that visual thalamus, in particular
the right LGN, is a key node in disturbed circuit function
underlying falls. FoG may be the result of striatal cholin-
ergic interneurons and limbic cholinergic nerve terminals,
with the right caudate nucleus as a key node in disturbed
control of gait.
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